BioNTech to highlight clinical results from CAR T program

By The Science Advisory Board staff writers

November 1, 2021 -- BioNTech plans to highlight new clinical data from a phase I/II trial of its BNT211 CAR T-cell therapy candidate at the Society for Immunotherapy of Cancer meeting in Washington, DC, on November 12.

BNT211 is an autologous CAR T-cell therapy that targets oncofetal antigen claudin 6 (CLDN6), according to the company. BNT211 is currently in trials for assessment as a monotherapy, as well as in combination with a CLDN6 mRNA-based vaccine (CARVac), for the treatment of relapsed or refractory advanced solid tumors, BioNTech said.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?